We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lonza and CELLINK Join Forces to Offer Complete 3D Cell Culture Workflows
Product News

Lonza and CELLINK Join Forces to Offer Complete 3D Cell Culture Workflows

Lonza and CELLINK Join Forces to Offer Complete 3D Cell Culture Workflows
Product News

Lonza and CELLINK Join Forces to Offer Complete 3D Cell Culture Workflows


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Lonza and CELLINK Join Forces to Offer Complete 3D Cell Culture Workflows"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lonza and the Swedish company CELLINK have partnered to offer a comprehensive 3-dimensional (3D) bioprinting solution designed to optimize and increase access to complete 3D cell culture workflows. The solution integrates CELLINK’s 3D bioprinting instruments and bioinks with Lonza’s broad selection of human-derived primary cells and supporting culture media.

Under the agreement, CELLINK will be delivering the complete 3D bioprinting solution through its global sales channels, supported by Lonza’s well-established logistics processes.

Cell biology laboratories on a global scale are increasingly adopting 3D over 2-dimensional (2D) cell culture approaches, as they more closely resemble the cells’ in vivo environment offering a more accurate and reliable means of predicting and analyzing cell behavior. However, as researchers look to create increasingly complex 3D constructs, finding solutions to structural and material engineering challenges is becoming progressively more important. 3D bioprinting has emerged as a powerful technology for engineering complex 3D tissues for in vitro drug discovery research.

CELLINK provides a wide range of user-friendly and flexible 3D bioprinting systems, designed to offer improved levels of sterility, precision and versatility. Furthermore, the company’s Bioink is the world’s first universal bioink designed to print complex 3D human tissue constructs with any 3D bioprinting system. Offering superior biocompatibility, cell viability, printability and consistency, this biomaterial can be modified with peptides and growth factors to develop a series of customized bioink formulations to meet varying application needs.

Robust, viable cells are an essential component of any successful 3D bioprinting and cell culture application. Lonza offers an extensive array of high-quality human-derived primary cells and culture media specifically developed to improve experimental reliability and validity. All cells are ethically sourced and authenticated by thorough quality control testing, while the media are optimized for each cell type to support optimal, consistent growth and maintain the tissue-specific characteristics.

Advertisement